Gyre Therapeutics (GYRE) Net Cash Flow (QoQ) (2010 - 2026)
Gyre Therapeutics (GYRE) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,316.27% |
| Mar 31, 2026 | 104.85% |
| Dec 31, 2025 | -192.09% |
| Sep 30, 2025 | -82.66% |
| Jun 30, 2025 | 573.73% |
| Mar 31, 2025 | 183.78% |
| Dec 31, 2024 | -1,027.00% |
| Sep 30, 2024 | 97.52% |
| Jun 30, 2024 | -270.04% |
| Mar 31, 2024 | -118.45% |
| Dec 31, 2023 | 2,732.24% |
| Sep 30, 2023 | 110.03% |
| Jun 30, 2023 | -40.56% |
| Mar 31, 2023 | 81.43% |
| Dec 31, 2022 | 48.59% |
| Sep 30, 2022 | -228.90% |
| Jun 30, 2022 | 525.78% |
| Mar 31, 2022 | 35.65% |
| Dec 31, 2021 | -2.39% |
| Sep 30, 2021 | -53.50% |